NRMI and current treatment patterns for ST-elevation myocardial infarction.
The National Registry of Myocardial Infarction (NRMI) is one of the oldest and largest registries of acute myocardial infarction (AMI). Since 1990, 4 NRMI studies have been launched, one of which is ongoing (Table I). In all, 1600 hospitals have participated and >2.2 million patients have been followed. This paper highlights some of our discoveries pertaining to ST-segment elevation and subsequent contributions to patient care.
Gibson
C Michael
CM
Harvard Medical School, Boston Mass, USA. mgibson@perfuse.org
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary / Q000706:statistics & numerical data*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D004562:Electrocardiography; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D014481:United States
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D005343:Fibrinolytic Agents; D001241:Aspirin